Genetic Technologies Limited offers predictive genetic testing and risk assessment tools globally. The company operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. BREVAGenplus is a clinically validated test for non-hereditary breast cancer. The company also markets tests for colorectal, breast, ovarian, prostate, pancreatic, melanoma, atrial fibrillation, and type 2 diabetes cancers. Genetic testing services include medical, animal, forensic, and plant testing. The company has research agreements with the University of Melbourne, Memorial Sloan Kettering Cancer Center, and the University of Cambridge. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Australia.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | -0.7 |